EUVIMEDObjevte EUVIMED
Multizentrische Studie

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure

Yanxue Lin iD, Xueping Yu iD, Huimin Lin, Jiajia Han, Yan Yan, Xiaoting Zhao, Yijie Lin, Zixuan Huang, Yinyin Zheng, Yahong Gao, Wenjin Yuan, Meifang Zhou and 2 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70213 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Yanxue Lin and 13 co-authors. Institution: Department of Infectious Diseases, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Major MEDLINE topics: Acute-On-Chronic Liver Failure, Hepatitis B, Chronic, Antiviral Agents, Nucleosides. Cited 2 times so far (Crossref); 39 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background/Aims Nucleos(t)ide analogues (NA) withdrawal is an important cause of hepatitis B virus (HBV) infection relapse or flare, potentially triggering HBV‐related acute‐on‐chronic liver failure (HBV‐ACLF). Although both NA withdrawal and spontaneous severe acute exacerbation (SAE) of chronic hepatitis B are recognised HBV‐ACLF triggers, comparative evidence regarding their distinct clinical trajectories remains absent. This multicenter retrospective cohort study sought to determine whether NA withdrawal independently predicts adverse outcomes in HBV‐related ACLF compared to SAE‐induced cases.

Methods

We retrospectively enrolled consecutive patients with HBV‐ACLF admitted to four tertiary hospitals in China. The relationship between NA withdrawal and all‐cause mortality in HBV‐ACLF patients was evaluated using multivariate Cox regression analysis. Additionally, sensitivity analyses including propensity score matching (PSM) and inverse probability treatment weighting (IPTW) were performed.

Results

Among the 313 HBV‐ACLF patients, 66 patients (21.1%) experienced NA withdrawal. HBV‐ACLF patients in the NA‐withdrawal group exhibited lower liver enzyme levels and higher infection rates at diagnosis compared with those in the NA‐naïve group. Multivariate Cox regression models indicated that, after adjusting for demographic and clinical confounders, NA withdrawal was significantly associated with 90‐day mortality (hazard ratio [HR], 1.610; 95% confidence interval [CI], 1.095–2.365; p = 0.015) and 180‐day mortality (HR, 1.549; 95% CI, 1.057–2.271; p = 0.025). Notably, the association remained consistent following PSM and IPTW.

Conclusions

NA withdrawal is an independent risk factor for death in patients with HBV‐ACLF, underlining the importance of adherence to NA therapy in patients with chronic hepatitis B.

Subjects

MeSH terms (MEDLINE)

Acute-On-Chronic Liver FailureHepatitis B, ChronicAntiviral AgentsNucleosidesNucleotidesHumansMaleFemaleRetrospective StudiesMiddle AgedAdultChinaTreatment OutcomeAged

Author keywords

clinical outcomeshepatitis B virus‐related acute‐on‐chronic liver failurenucleos(t)ide analogue withdrawalretrospective cohort study

Substances

Antiviral AgentsNucleosidesNucleotides

Authors and institutions

  • Department of Infectious Diseases, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Infectious Diseases, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Infection Disease, Clinical Medical Research Center for Bacterial and Fungal Infectious Diseases of Fujian Province, Fujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, Fujian, China.
  • Key Laboratory of Screening and Control of Infectious Diseases (Quanzhou Medical College), Fujian Provincial University, Quanzhou, Fujian, China.
  • Hepatology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China.
  • Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Clinical Research Center for Liver and Intestinal Diseases of Fujian Province, Fuzhou, China.

ORCID profiles: Yanxue Lin, Xueping Yu, Jiming Zhang, Dawu Zeng

Cite

APA

Lin, Y., Yu, X., Lin, H., Han, J., Yan, Y., Zhao, X., Lin, Y., Huang, Z., Zheng, Y., Gao, Y., Yuan, W., Zhou, M., Zhang, J., & Zeng, D. (2025). Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70213

Vancouver

Lin Y, Yu X, Lin H, Han J, Yan Y, Zhao X, et al. Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70213

BibTeX
@article{Lin2025,
  author = {Lin, Yanxue and Yu, Xueping and Lin, Huimin and Han, Jiajia and Yan, Yan and Zhao, Xiaoting and Lin, Yijie and Huang, Zixuan and Zheng, Yinyin and Gao, Yahong and Yuan, Wenjin and Zhou, Meifang and Zhang, Jiming and Zeng, Dawu},
  title = {Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70213}
}
Start for free →